Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations in India, the United States, Europe, and internationally. It's primary oncology and non-oncology APIs include capecitabine, gemcitabine hydrochloride, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride, as well as ambroxol, tranexmic acid, and ursodeoxycholic acid; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.